Literature DB >> 16138117

The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

V Baron1, E D Adamson, A Calogero, G Ragona, D Mercola.   

Abstract

Recent studies are reviewed indicating that the transcription factor early growth response-1 (Egr1) is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. The downstream pathways of these factors display multiple nodes of interaction with each other, suggesting the existence of a functional network of suppressor factors that serve to maintain normal growth regulation and resist the emergence of transformed variants. Paradoxically, Egr1 is oncogenic in prostate cancer. In the majority of these cancers, PTEN or p53 is inactive. It is suggested that these defects in the suppressor network allow for the unopposed induction of TGFbeta1 and fibronectin, which favor transformation and survival of prostate tumor epithelial cells, and explain the role of Egr1 in prostate cancer. Egr1 is a novel and logical target for intervention by gene therapy methods, and targeting methods are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16138117      PMCID: PMC2455793          DOI: 10.1038/sj.cgt.7700896

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  87 in total

1.  Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation.

Authors:  R P Huang; Y Fan; I deBelle; Z Ni; W Matheny; E D Adamson
Journal:  Cell Death Differ       Date:  1998-01       Impact factor: 15.828

Review 2.  Molecular targeting of gene therapy and radiotherapy.

Authors:  R R Weichselbaum; D W Kufe; S J Advani; B Roizman
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

Review 3.  Fibronectin and its integrin receptors in cancer.

Authors:  E Ruoslahti
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

4.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

5.  The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling.

Authors:  T Virolle; E D Adamson; V Baron; D Birle; D Mercola; T Mustelin; I de Belle
Journal:  Nat Cell Biol       Date:  2001-12       Impact factor: 28.824

6.  Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma.

Authors:  S A Abdulkadir; J M Carbone; C K Naughton; P A Humphrey; W J Catalona; J Milbrandt
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

7.  Regulation of constitutive expression of mouse PTEN by the 5'-untranslated region.

Authors:  Baoguang Han; Zizheng Dong; Yang Liu; Qun Chen; Katsuyuki Hashimoto; Jian-Ting Zhang
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

Review 8.  Chromosomal deletions and tumor suppressor genes in prostate cancer.

Authors:  J T Dong
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

9.  Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.

Authors:  Carlos A Lopez; Eric T Kimchi; Helena J Mauceri; James O Park; Neil Mehta; Kevin T Murphy; Michael A Beckett; Samuel Hellman; Mitchell C Posner; Donald W Kufe; Ralph R Weichselbaum
Journal:  Mol Cancer Ther       Date:  2004-09       Impact factor: 6.261

Review 10.  Potential role of HBGF (FGF) and TGF-beta on prostate growth.

Authors:  Y Matuo; W L McKeehan; G C Yan; S Nikolaropoulos; P S Adams; Y Fukabori; H Yamanaka; J Gaudreau
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

View more
  161 in total

1.  Genetic background-dependent role of Egr1 for eyelid development.

Authors:  Jangsuk Oh; Yujuan Wang; Shida Chen; Peng Li; Ning Du; Zu-Xi Yu; Donna Butcher; Tesfay Gebregiorgis; Erin Strachan; Ordan J Lehmann; Brian P Brooks; Chi-Chao Chan; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-04       Impact factor: 11.205

Review 2.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

3.  Age-associated up-regulation of EGR1 promotes granulosa cell apoptosis during follicle atresia in mice through the NF-κB pathway.

Authors:  Suzhen Yuan; Jingyi Wen; Jing Cheng; Wei Shen; Su Zhou; Wei Yan; Lu Shen; Aiyue Luo; Shixuan Wang
Journal:  Cell Cycle       Date:  2016-07-19       Impact factor: 4.534

4.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

5.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

Review 6.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.

Authors:  Christopher M Cabello; Sarah D Lamore; Warner B Bair; Angela L Davis; Sara M Azimian; Georg T Wondrak
Journal:  Free Radic Res       Date:  2010-11-01

8.  Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2.

Authors:  Jernej Kristl; Petra Slanc; Metka Krasna; Ales Berlec; Matjaz Jeras; Borut Strukelj
Journal:  Pharm Res       Date:  2007-08-02       Impact factor: 4.200

9.  Enthalpic factors override the polyelectrolyte effect in the binding of EGR1 transcription factor to DNA.

Authors:  David C Mikles; Vikas Bhat; Brett J Schuchardt; Caleb B McDonald; Amjad Farooq
Journal:  J Mol Recognit       Date:  2014-02       Impact factor: 2.137

Review 10.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; John M Joslin; Thelma R Tennant; Shalini C Reshmi; David J Young; Angela Stoddart; Richard A Larson; Michelle M Le Beau
Journal:  Chem Biol Interact       Date:  2009-12-01       Impact factor: 5.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.